Loading...

BELLUS Health

DB:BHN
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BHN
DB
CA$229M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
  • BELLUS Health has significant price volatility in the past 3 months.
BHN Share Price and Events
7 Day Returns
-7%
DB:BHN
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
226.2%
DB:BHN
-10.2%
DE Biotechs
-6%
DE Market
BHN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BELLUS Health (BHN) -7% -6.3% 42.5% 226.2% -19.5% 67.4%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • BHN outperformed the Biotechs industry which returned -10.2% over the past year.
  • BHN outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
BHN
Industry
5yr Volatility vs Market

BHN Value

 Is BELLUS Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BELLUS Health. This is due to cash flow or dividend data being unavailable. The share price is €0.946.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BELLUS Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BELLUS Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BHN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$-0.08
TSX:BLU Share Price ** TSX (2019-04-18) in CAD CA$1.45
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BELLUS Health.

DB:BHN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:BLU Share Price ÷ EPS (both in CAD)

= 1.45 ÷ -0.08

-19.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BELLUS Health is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BELLUS Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BELLUS Health's expected growth come at a high price?
Raw Data
DB:BHN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-43.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BELLUS Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BELLUS Health's assets?
Raw Data
DB:BHN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$0.32
TSX:BLU Share Price * TSX (2019-04-18) in CAD CA$1.45
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:BHN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:BLU Share Price ÷ Book Value per Share (both in CAD)

= 1.45 ÷ 0.32

4.5x

* Primary Listing of BELLUS Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BELLUS Health is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BELLUS Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BELLUS Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BHN Future Performance

 How is BELLUS Health expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-43.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BELLUS Health expected to grow at an attractive rate?
  • Unable to compare BELLUS Health's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare BELLUS Health's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • BELLUS Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BHN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BHN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -43.4%
DB:BHN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 67.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BHN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BHN Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 94 59 1
2022-12-31 83 57 1
2021-12-31 8 -5 1
2020-12-31 2 142 -23 2
2019-12-31 0 -8 -15 2
DB:BHN Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -10 -9
2018-09-30 0 -8 -8
2018-06-30 0 -8 -7
2018-03-31 0 -6 -5
2017-12-31 0 -4 -2
2017-09-30 1 -4 -1
2017-06-30 1 -3 0
2017-03-31 1 -3 0
2016-12-31 2 -3 -2
2016-09-30 4 -3 -1
2016-06-30 4 -3 0
2016-03-31 4 -3 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BELLUS Health is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • BELLUS Health's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BHN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from BELLUS Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BHN Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -0.13 -0.13 -0.13 1.00
2019-12-31 -0.10 -0.10 -0.10 1.00
DB:BHN Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 -0.08
2018-09-30 -0.07
2018-06-30 -0.07
2018-03-31 -0.06
2017-12-31 -0.03
2017-09-30 -0.01
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 -0.04
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • BELLUS Health is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess BELLUS Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BELLUS Health has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BHN Past Performance

  How has BELLUS Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BELLUS Health's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BELLUS Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BELLUS Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BELLUS Health's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BELLUS Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BELLUS Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BHN Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.04 -9.08 3.41 6.53
2018-09-30 0.05 -8.06 3.39 5.06
2018-06-30 0.13 -6.69 3.07 4.11
2018-03-31 0.17 -4.86 2.67 4.32
2017-12-31 0.17 -1.87 2.53 3.32
2017-09-30 0.50 -0.77 2.28 2.74
2017-06-30 0.77 0.30 2.38 1.87
2017-03-31 1.31 -0.29 2.20 1.33
2016-12-31 1.89 -2.16 2.62 1.37
2016-09-30 3.59 -0.80 2.94 1.34
2016-06-30 3.82 -0.38 2.90 1.35
2016-03-31 3.83 -0.48 3.39 0.97
2015-12-31 4.02 0.20 3.12 1.01
2015-09-30 3.03 -0.47 2.81 1.29
2015-06-30 2.86 -0.99 3.00 1.35
2015-03-31 2.69 -1.30 2.98 1.55
2014-12-31 2.38 -1.93 3.15 1.70
2014-09-30 2.06 -2.63 3.73 1.55
2014-06-30 2.17 -0.89 3.66 1.46
2014-03-31 2.13 -1.02 3.95 1.34
2013-12-31 2.26 -0.87 4.02 1.27
2013-09-30 2.05 -0.69 2.60 1.02
2013-06-30 2.01 -1.99 2.64 0.92
2013-03-31 2.33 -10.60 3.38 1.02
2012-12-31 2.30 -13.26 3.69 0.95
2012-09-30 2.61 -15.15 4.87 0.91
2012-06-30 2.88 -14.65 4.82 0.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BELLUS Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BELLUS Health has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BELLUS Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BELLUS Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BELLUS Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BHN Health

 How is BELLUS Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BELLUS Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BELLUS Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BELLUS Health has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BELLUS Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BELLUS Health has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BELLUS Health Company Filings, last reported 3 months ago.

DB:BHN Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 50.58 0.00 48.91
2018-09-30 20.62 0.00 18.10
2018-06-30 23.21 0.00 20.25
2018-03-31 24.58 0.00 21.73
2017-12-31 26.29 0.00 23.89
2017-09-30 9.27 0.00 6.30
2017-06-30 10.86 0.00 6.27
2017-03-31 10.94 0.00 7.02
2016-12-31 8.26 0.00 6.83
2016-09-30 9.00 0.00 7.21
2016-06-30 9.57 0.00 7.95
2016-03-31 9.77 0.00 8.95
2015-12-31 10.37 0.00 9.70
2015-09-30 9.32 0.00 10.14
2015-06-30 9.30 0.00 10.68
2015-03-31 9.60 0.00 11.54
2014-12-31 9.51 0.00 12.31
2014-09-30 9.15 5.19 13.28
2014-06-30 9.75 5.19 13.68
2014-03-31 10.27 5.19 14.63
2013-12-31 10.82 5.19 15.88
2013-09-30 11.23 5.19 16.00
2013-06-30 10.02 5.20 15.66
2013-03-31 10.71 8.25 19.36
2012-12-31 11.08 8.25 18.57
2012-09-30 11.13 8.30 19.07
2012-06-30 11.33 8.58 21.18
  • BELLUS Health has no debt.
  • BELLUS Health has no debt compared to 5 years ago when it was 48%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BELLUS Health has sufficient cash runway for more than 3 years based on current free cash flow.
  • BELLUS Health has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 46% each year.
X
Financial health checks
We assess BELLUS Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BELLUS Health has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BHN Dividends

 What is BELLUS Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BELLUS Health dividends.
If you bought €2,000 of BELLUS Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BELLUS Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BELLUS Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BHN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BHN Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BELLUS Health has not reported any payouts.
  • Unable to verify if BELLUS Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BELLUS Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BELLUS Health has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BELLUS Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BELLUS Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BELLUS Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BHN Management

 What is the CEO of BELLUS Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Roberto Bellini
COMPENSATION CA$1,001,729
AGE 38
TENURE AS CEO 9.3 years
CEO Bio

Mr. Roberto Bellini has been the Chief Executive Officer and President of BELLUS Health Inc, since January 1, 2010. Mr. Bellini served as an Executive Vice President of Picchio Pharma Inc. until January 1, 2010. He served as a Vice President of Business Development at BELLUS Health Inc. from June 04, 2009 to January 01, 2010. He has been a Director at BELLUS Health Inc. since 2009. Mr. Bellini served as a Director of Thallion Pharmaceuticals, Inc., from March 2007 to April 24, 2013. He holds a Bachelor of Science in Biochemistry from McGill University.

CEO Compensation
  • Roberto's compensation has increased whilst company is loss making.
  • Roberto's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BELLUS Health management team in years:

9.3
Average Tenure
45
Average Age
  • The average tenure for the BELLUS Health management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Roberto Bellini

TITLE
President
COMPENSATION
CA$1M
AGE
38
TENURE
9.3 yrs

François Desjardins

TITLE
Vice President of Finance
COMPENSATION
CA$362K
AGE
55
TENURE
9.8 yrs

Denis Garceau

TITLE
Senior Vice President of Drug Development
COMPENSATION
CA$602K
AGE
61
TENURE
14.3 yrs

Tony Matzouranis

TITLE
Vice President of Business Development
COMPENSATION
CA$376K
AGE
45
TENURE
7.2 yrs

Sébastien Roy

TITLE
Corporate Secretary
AGE
42
TENURE
8.2 yrs
Board of Directors Tenure

Average tenure and age of the BELLUS Health board of directors in years:

1.8
Average Tenure
57
Average Age
  • The average tenure for the BELLUS Health board of directors is less than 3 years, this suggests a new board.
Board of Directors

Francesco Bellini

TITLE
Chairman
COMPENSATION
CA$322K
AGE
70

Roberto Bellini

TITLE
President
COMPENSATION
CA$1M
AGE
38
TENURE
10.3 yrs

Joseph Rus

TITLE
Director
COMPENSATION
CA$109K
AGE
72
TENURE
10.3 yrs

Pierre Larochelle

TITLE
Lead Director
COMPENSATION
CA$141K
AGE
46

Jaclyn Smith

TITLE
Chairman of the Clinical Advisory Board
TENURE
0.6 yrs

Franklin Berger

TITLE
Director
COMPENSATION
CA$95K
AGE
69
TENURE
8.9 yrs

Youssef Bennani

TITLE
Director
COMPENSATION
CA$96K
AGE
57
TENURE
1.9 yrs

Clarissa Desjardins

TITLE
Director
COMPENSATION
CA$88K
AGE
51
TENURE
1.6 yrs

Alan Goldsobel

TITLE
Member of Clinical Advisory Board
TENURE
0.6 yrs

Lorcan McGarvey

TITLE
Member of Clinical Advisory Board
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Dec 18 Buy OrbiMed Advisors, L.L.C. Company 18. Dec 18 18. Dec 18 16,899,800 €0.62 €10,487,293
18. Dec 18 Buy Clarissa Desjardins Individual 18. Dec 18 18. Dec 18 52,632 €0.62 €32,661
18. Dec 18 Buy Franklin Berger Individual 18. Dec 18 18. Dec 18 263,158 €0.62 €163,305
18. Dec 18 Buy Francesco Bellini Individual 18. Dec 18 18. Dec 18 269,710 €0.62 €167,370
27. Nov 18 Buy Roberto Bellini Individual 26. Nov 18 26. Nov 18 100,000 €0.61 €61,188
22. Nov 18 Buy Francesco Bellini Individual 20. Nov 18 20. Nov 18 200,000 €0.58 €111,236
X
Management checks
We assess BELLUS Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BELLUS Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BHN News

Simply Wall St News

BHN Company Info

Description

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer’s disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Details
Name: BELLUS Health Inc.
BHN
Exchange: DB
Founded: 1993
CA$152,344,259
157,957,111
Website: http://www.bellushealth.com
Address: BELLUS Health Inc.
275 Armand-Frappier Boulevard,
Laval,
Quebec, H7V 4A7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX BLU Common Shares The Toronto Stock Exchange CA CAD 22. Jun 2000
OTCPK BLUS.F Common Shares Pink Sheets LLC US USD 22. Jun 2000
DB BHN Common Shares Deutsche Boerse AG DE EUR 22. Jun 2000
LSE 0UL1 Common Shares London Stock Exchange GB CAD 22. Jun 2000
Number of employees
Current staff
Staff numbers
10
BELLUS Health employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 20:58
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/02/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.